Milvexian在轻度或中度肝损伤患者中的单剂量药代动力学
本研究为开放标签、单剂量、平行对照研究,评估60 mg milvexian在轻度(n=9)或中度(n=8)肝损伤患者与肝功能正常者(n=9)中的药代动力学。结果显示,轻中度肝损伤患者中milvexian暴露未见有临床意义的改变,且耐受性良好,提示可能无需调整剂量。
要点
- 轻中度肝损伤患者单剂量60 mg milvexian耐受性良好,无严重不良事件或出血事件。
- 轻度肝损伤相比正常肝功能,总milvexian的Cmax和AUC0-inf几何均值比分别为1.180和1.168,90%CI均包含1。
- 中度肝损伤相比正常肝功能,总milvexian的Cmax和AUC0-inf几何均值比分别为1.140和0.996,90%CI均包含1。
核心结论
- Milvexian在肝功能正常、轻度损伤和中度损伤受试者中均耐受良好。
- 观察到的药代动力学变化提示轻度或中度肝损伤患者可能无需调整剂量。
研究设计与样本
- 开放标签、单剂量、平行对照研究。
- 受试者接受单次口服milvexian 60 mg。
- 轻度肝损伤组n=9,中度肝损伤组n=8,肝功能正常组n=9。
- 健康受试者按体重、年龄和性别与肝损伤受试者匹配。
- 对自然对数转换后的milvexian暴露参数进行方差分析,以肝功能分组为固定效应。
主要发现
- 单次60 mg milvexian总体耐受良好,无严重不良事件、出血不良事件或因不良事件停药。
- 轻度肝损伤 vs 正常肝功能:总milvexian Cmax几何均值比1.180(90%CI 0.735-1.895),AUC0-inf几何均值比1.168(90%CI 0.725-1.882)。
- 中度肝损伤 vs 正常肝功能:总milvexian Cmax几何均值比1.140(90%CI 0.699-1.857),AUC0-inf几何均值比0.996(90%CI 0.609-1.628)。
- 各组中均观察到活化部分凝血活酶时间随milvexian暴露增加而延长。
临床怎么用
- 对于轻度或中度肝损伤患者,使用milvexian可能无需根据肝功能进行剂量调整。
- 用药期间仍需关注出血风险,尤其对于肝损伤患者。
局限性
- 研究为单剂量设计,未评估多次给药后的药代动力学。
- 样本量较小(每组8-9例),可能影响统计效能。
- 未纳入重度肝损伤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with hepatic impairment receiving antithrombotic agents metabolized primarily through the liver can be at risk for bleeding. Milvexian (BMS-986177/JNJ-70033093) is a small-molecule, active-site inhibitor of activated Factor XI (FXIa). Modulation of FXI may provide systemic anticoagulation without increased risk of clinically significant bleeding. OBJECTIVE: This open-label study evaluated the effects of mild or moderate hepatic impairment on the pharmacokinetics of milvexian to assess their impact on safety and dosing. METHODS: Single doses of milvexian 60 mg were administered to participants with mild hepatic impairment (n = 9), moderate hepatic impairment (n = 8), and normal hepatic function (n = 9). Healthy participants were matched to participants with hepatic impairment by body weight, age, and sex. Analysis of variance was performed on natural log-transformed milvexian exposure parameters, with hepatic function group as a fixed effect. RESULTS: Single doses of milvexian 60 mg were generally well tolerated, with no serious adverse events (AEs), bleeding AEs, or discontinuations due to AEs. Geometric mean ratios (90% confidence interval) for total milvexian maximum observed plasma concentration and area under the plasma concentration-time curve from time zero extrapolated to infinite time were 1.180 (0.735-1.895) and 1.168 (0.725-1.882), respectively, for mild hepatic impairment versus normal hepatic function and 1.140 (0.699-1.857) and 0.996 (0.609-1.628), respectively, for moderate hepatic impairment versus normal hepatic function. Across groups, milvexian exposure-related increases were observed for activated partial thromboplastin time. CONCLUSION: Milvexian was well tolerated in participants with normal, mildly impaired, and moderately impaired hepatic function. Observed pharmacokinetic changes suggest it is unlikely that dose adjustments will be necessary in patients with mild or moderate hepatic impairment. Clinical Trial RegistrationClinicaltrials.gov identifier: NCT02982707.
引用
- Perera V, Abelian G, Li D, et al. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clin Pharmacokinet. 2022. PMID: 35262846. doi:10.1007/s40262-022-01110-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。